Drug Trial Radar · NCT00744263
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
Last checked: Nov 19, 2026Latest source record: Oct 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84,496
Actual
Start
Sep 2008
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 29, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
Conditions
- Pneumonia, Pneumococcal
- Pneumococcal Infections
- 13-valent Pneumococcal Vaccine
Interventions
VACCINE: placeboBiological
0.5 mL, single intra-muscular injection
VACCINE: 13-valent pneumococcal conjugate vaccineBiological
0.5 mL, single intra-muscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)Time frame: Baseline up to occurrence of first episode of VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)
Locations
159 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Abbekerk, Netherlands
Pfizer Investigational Site
Alkmaar, Netherlands
Pfizer Investigational Site
Alkmaar, Netherlands
Pfizer Investigational Site
Almelo, Netherlands
Pfizer Investigational Site
Almere Stad, Netherlands
Pfizer Investigational Site
Almere Stad, Netherlands
Pfizer Investigational Site
Alphen aan den Rijn, Netherlands
Pfizer Investigational Site
Amersfoort, Netherlands
Pfizer Investigational Site
Amersfoort, Netherlands
Pfizer Investigational Site
Amstelveen, Netherlands
Pfizer Investigational Site
Amstelveen, Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands
Pfizer Investigational Site
Apeldoorn, Netherlands
Pfizer Investigational Site
Apeldoorn, Netherlands
Pfizer Investigational Site
Apeldoorn, Netherlands
Pfizer Investigational Site
Arnhem, Netherlands
Pfizer Investigational Site
Arnhem, Netherlands
Pfizer Investigational Site
Assen, Netherlands
Pfizer Investigational Site
Assen, Netherlands
Pfizer Investigational Site
Baarle-Nassau, Netherlands
Pfizer Investigational Site
Baarn, Netherlands
Pfizer Investigational Site
Bedum, Netherlands
Pfizer Investigational Site
Bennebroek, Netherlands
Pfizer Investigational Site
Bergen op Zoom, Netherlands
Pfizer Investigational Site
Bergen op Zoom, Netherlands
Pfizer Investigational Site
Berkel-Enschot, Netherlands
Pfizer Investigational Site
Berkhout, Netherlands
Pfizer Investigational Site
Bilthoven, Netherlands
Pfizer Investigational Site
Blaricum, Netherlands
Pfizer Investigational Site
Breda, Netherlands
Pfizer Investigational Site
Breda, Netherlands
Pfizer Investigational Site
Breda, Netherlands
Pfizer Investigational Site
Brunssum, Netherlands
Pfizer Investigational Site
Deventer, Netherlands
Showing 40 of 159 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.